Table 1.
Patients characteristics and clinical outcomes.
| Characteristics | Results |
|---|---|
| Age (years) | 49.8 ± 8.0 |
| BMI (kg/m2) | 23.7 ± 3.3 |
| AJCC stage | |
| I | 35 (41.1) |
| II | 32 (37.6) |
| III | 18 (21.2) |
| T stage | |
| 1 | 40 (47.1) |
| 2 | 35 (41.2) |
| 3 | 10 (11.8) |
| N stage | |
| 0 | 55 (64.7) |
| 1 | 15 (17.6) |
| 2 | 8 (9.4) |
| 3 | 7 (8.2) |
| Histologic type | |
| Invasive ductal carcinoma | 77 (90.6) |
| Others | 8 (9.4) |
| Histologic grade | |
| 1 | 16 (18.8) |
| 2 | 38 (44.7) |
| 3 | 29 (34.1) |
| Unknown | 2 (2.4) |
| Hormone receptor status | |
| ER positive | 58 (68.2) |
| PR positive | 48 (56.5) |
| HER2 positive | 27 (31.8) |
| Surgery type | |
| Total mastectomy | 46 (54.1) |
| Partial mastectomy | 39 (45.9) |
| Treatment type | |
| Chemotherapy | |
| Neoadjuvant chemotherapy | 9 (10.6) |
| Adjuvant chemotherapy | 76 (89.4) |
| Hormonal therapy | 65 (76.5) |
| Radiotherapy | 53 (62.4) |
| Clinical outcomes | |
| Death | 6 (7.1) |
| Recurrence | 10 (11.8) |
| Grade 4 neutropenia | 20 (23.5) |
Data, excluding clinical outcomes, are gathered at the time of diagnosis. Data are expressed as the number of patients with percentages in parentheses or mean ± standard deviation. Temporal data are expressed as median ± standard deviation.
BMI body mass index, AJCC American Joint Committee on Cancer, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor 2.